Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PIM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | PIM2 Active Recombinant Protein (Full-Length Kinase) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. ATP-binding site intact. |
View PIM2 Products |
| Mutant Panel | PIM2 Resistance Mutants (Gatekeeper & Activation Loop) For selectivity and resistance profiling. Endotoxin Controlled. |
View PIM2 Products |
| Gene Delivery | PIM2 ORF Lentivirus / Premade Particles CMV promoter, Puromycin selection. For stable cell line construction. |
View PIM2 Products |
| Benchmark Ab | Anti-PIM2 Recombinant Antibody Recombinant positive control for WB and IHC. |
View PIM2 Products |
| Validator | PIM2 siRNA Set (3 unique targets) For knockdown verification and specificity controls. |
View PIM2 Products |
| Related Target A | PIM1 Isoform selectivity screening (high homology, distinct biology). |
View PIM1 Products |
| Related Target B | PIM3 Off-target liability panel for pan-PIM inhibitors. |
View PIM3 Products |
| Related Target C | MYC Downstream oncogenic driver stabilized by PIM2. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PIM1/2/3 paralog discrimination) | Human PIM1, PIM2, PIM3 active kinases available as parallel panel; Sequence Verified; >95% purity with verified kinase activity |
| Resistance Mutation Screening (Gatekeeper/Activation loop) | PIM2 Mutant Proteins (e.g., gatekeeper analogs) expressed in HEK293; Native folding confirmed by specific activity |
| Cellular Context Validation (Substrate phosphorylation) | High-titer PIM2 Lentivirus for stable overexpression; Compatible with pBAD/p4EBP1 reporter assays |
| Lack of Controls | Validated pathway antibodies included |
| False Positives | Sequence Verified siRNA included for specificity checks |
| Biochemical Kinase Assays | Highly active recombinant PIM2, HEK293 or Baculovirus expressed |
Live PIM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PIM2 therapeutics is intensifying, with major players shifting focus from early pan-PIM inhibitors to highly selective PIM2-targeted modalities and proteolysis-targeting chimeras (PROTACs). As first-generation ATP-competitive inhibitors face challenges with hematologic toxicity and isoform redundancy, the next wave of R&D is targeting allosteric sites, CNS-penetrant formulations, and combination therapies to overcome PI3K/mTOR inhibitor resistance in multiple myeloma and AML. Key emerging indications include diffuse large B-cell lymphoma (DLBCL) and central nervous system lymphoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Pan-PIM / ATP-competitive) | Novartis, Incyte, Tolero Pharma (TP-3654) | Multiple Myeloma, AML, Myelofibrosis | Kinase Activity & Selectivity Assay (Need high-purity active PIM1/2/3 with intact ATP-binding site) |
| Small Molecule (PIM2 Selective) | Preclinical Biotech, AstraZeneca (Isoform-selective) | Refractory AML, Solid Tumors (CNS penetration) | Binding Kinetic & Paralog Selectivity Panel (Need high-purity kinase domains + mutant proteins) |
| PROTAC / Degrader | Academic Consortia, Nurix | Multiple Myeloma, Prostate Cancer | Cellular Degradation Assay (Need Lentivirus-based stable PIM2 cell lines & biotinylated PIM2 for ternary complex) |
| Combinatorial RNAi | Specialized biotech | AML Combination Therapy | Knockdown Validation (Need validated siRNA and shRNA Lentivirus) |
Key Mutations & Functional Domain Insights
PIM2 is a serine/threonine kinase (UniProt Q9P1W9). Documented mutations include dbSNP:rs35044770 and dbSNP:rs35208542 (UniProt VAR_041008, VAR_041009). These variants are critical for understanding resistance mechanisms and designing selective inhibitors. TarMart provides wild-type and mutant PIM2 proteins to support such studies.